Dimension Therapeutics, Inc. (DMTX) Expected to Announce Earnings of -$0.49 Per Share
Equities research analysts expect Dimension Therapeutics, Inc. (NASDAQ:DMTX) to post earnings per share of ($0.49) for the current quarter, Zacks reports. Zero analysts have made estimates for Dimension Therapeutics’ earnings. Dimension Therapeutics reported earnings per share of ($0.58) in the same quarter last year, which suggests a positive year-over-year growth rate of 15.5%. The company is expected to announce its next quarterly earnings report on Thursday, November 9th.
According to Zacks, analysts expect that Dimension Therapeutics will report full-year earnings of ($1.99) per share for the current year. For the next year, analysts forecast that the business will report earnings of ($1.50) per share, with EPS estimates ranging from ($2.20) to ($0.80). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Dimension Therapeutics.
Dimension Therapeutics (NASDAQ:DMTX) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.49). Dimension Therapeutics had a negative net margin of 358.21% and a negative return on equity of 98.72%. The business had revenue of $4.37 million during the quarter.
DMTX has been the subject of several research reports. Canaccord Genuity reduced their price target on shares of Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, June 28th. Cantor Fitzgerald set a $3.00 price target on shares of Dimension Therapeutics and gave the company a “hold” rating in a research report on Saturday, June 10th. Chardan Capital reissued a “hold” rating on shares of Dimension Therapeutics in a research report on Monday, August 14th. Finally, Zacks Investment Research downgraded shares of Dimension Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $3.33.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Weiss Multi Strategy Advisers LLC boosted its holdings in Dimension Therapeutics by 6.7% during the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock worth $683,000 after acquiring an additional 24,489 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Dimension Therapeutics by 206.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 54,231 shares during the last quarter. Finally, Two Sigma Securities LLC purchased a new position in Dimension Therapeutics during the 1st quarter worth $108,000. 70.75% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/15/dimension-therapeutics-inc-dmtx-expected-to-announce-earnings-of-0-49-per-share.html.
Dimension Therapeutics (NASDAQ DMTX) opened at 4.10 on Friday. The firm’s market cap is $102.71 million. Dimension Therapeutics has a one year low of $1.05 and a one year high of $9.98. The company’s 50-day moving average is $2.20 and its 200 day moving average is $1.65.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.